Majlis turut menyaksikan pelancaran buku iLawanLupus: A Patient Dialogue hasil kerjasama PSLEM dan AstraZeneca bagi meningkatkan pemahaman orang ramai tentang penyakit SLE, dan akan diedarkan sebagai ...

Majlis turut menyaksikan pelancaran buku iLawanLupus: A Patient Dialogue hasil kerjasama PSLEM dan AstraZeneca bagi meningkatkan pemahaman orang ramai tentang penyakit SLE, dan akan diedarkan sebagai ...

Guru yang menghidap Sistemetik Lupus Eritematosus (SLE) ini turut mengalami keretakan pada tulang bahu namun, pembedahan tidak boleh dilakukan kerana penyakit SLE yang dihidapi. Bercerita lanjut ...

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...

Patients with intermediate-onset lupus nephritis were associated with poorer renal outcomes compared against those with early-onset disease. Patients who develop lupus nephritis (LN) within 1 to 5 ...

SANTA MONICA, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (Nasdaq: SLE) (the “Company”), a leader in engaging audiences through playable media, content, and ...

Super League Enterprise, Inc. creates and publishes content experiences and media solutions across immersive platforms in the United States and internationally. Its proprietary cloud-based ...

Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal of the American Society of ...

Systemic lupus erythematosus (SLE) is an autoimmune disease that sometimes involves the central nervous system in a condition known as neuropsychiatric SLE (NPSLE). Research in mice has shown that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.